Study to Evaluate Safety and Effects of IV LY4006896 in Healthy Adults and Adults With Parkinsons Disease

What this Trial Is About

This trial investigates the safety, tolerability, and how the body processes a drug called LY4006896 compared with a placebo in both healthy adults and adults with Parkinsons disease. The study is a phased clinical trial aiming to gather early evidence on these aspects for LY4006896, with participants including healthy individuals and those diagnosed with Parkinsons disease. Healthy participants will receive a single escalating intravenous dose of LY4006896 or a matching placebo, while participants with Parkinsons disease will receive multiple escalating intravenous doses or placebo. The study includes a screening period of up to 120 days for Parkinsons participants who get 4 doses, and up to 35 days for healthy participants who receive 1 dose. Treatment and follow-up last up to 61 weeks for Parkinsons participants and 48 weeks for healthy participants. Participants will undergo various assessments including monitoring for serious and treatment-emergent adverse events up to 48 weeks for healthy participants and 61 weeks for those with Parkinsons disease. Researchers will measure drug levels in the body and examine effects on alpha-synuclein protein in skin and cerebrospinal fluid. The total study duration can be up to 78 weeks for Parkinsons participants and 53 weeks for healthy participants, with ongoing safety and pharmacokinetic evaluations throughout.

A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease